Loading
Siga Technologies Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Kane Julie, was filed 10 Dec 2019.
Siga Technologies Inc: what insiders have been doing
This page follows insider dealings at Siga Technologies Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 22 October 2026, 16 filings were filed, from 6 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
With 16 filings in twelve months, the company is quieter than the median of 24 filings across the 3,171 companies we follow on the same exchange. Over the whole record (from 2016), the tally stands at 11 purchases and 9 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 94.6 m USD and net income at 23.3 m USD; the dividend was 0.60 USD per share.
No insider has bought Siga Technologies Inc shares on the open market in the past twelve months. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
225
Thresholds
n/a
Buy Volume
€466,677
11 ops. · all time
Sell Volume
€1M
9 ops. · all time
Since the insiders bought
- +49.9%Entry US$4.67 · Close at T+365 US$7.00
- +49.9%Entry US$4.67 · Close at T+365 US$7.00
- +49.9%Entry US$4.67 · Close at T+365 US$7.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,825 of 26,246 companies
76.9
score / 100
Value79
Quality75
FCF yld19%
Earn yld10%
EV/EBITDA9.4x
ROE-1.5%
Gross mgn69%
Net mgn25%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.16
Analyst consensus
0.00/5
Income statement
RevenueUS$94.6M
Gross profitUS$64.9M69% margin
EBITDAUS$24.3M26% margin
Net incomeUS$23.3M-5.2% margin
Valuation
PER (trailing)11.7x
PER (forward)2.9x
P/Book1.4x
Beta0.96
Balance sheet & cash
Market capUS$226.7M
Total debtUS$595.2k
Free Cash FlowUS$43.1M
Debt / Equity0%
Profitability & ownership
ROE-1.5%
ROA-3.4%
% insiders42.7%
% institutions50.2%
Last declaration on 10 June 2026
Declarations225 total
24,116 sharesCommon Stock, par value $.0001 per shareSEC:0001193125-26-266399:0
7,235 sharesCommon Stock, par value $.0001 per shareSEC:0001193125-26-266399:1
24,116 sharesCommon Stock, par value $.0001 per shareSEC:0001193125-26-266414:0
7,235 sharesCommon Stock, par value $.0001 per shareSEC:0001193125-26-266414:1
3,526 shares@ US$4.996.1% of flowCommon Stock, par value $.0001 per shareSEC:0001193125-26-126758:1
6,920 shares0Common Stock, par value $.0001 per shareSEC:0001193125-26-126758:0
6,074 shares@ US$5.263.1% of flowCommon Stock, par value $.0001 per shareSEC:0001193125-26-110801:1
47,029 shares@ US$5.2633.6% of flowCommon Stock, par value $.0001 per shareSEC:0001193125-26-110759:1
3,955 shares@ US$5.261.1% of flowCommon Stock, par value $.0001 per shareSEC:0001193125-26-110790:1
11,187 shares@ US$5.2620.7% of flowCommon Stock, par value $.0001 per shareSEC:0001193125-26-110770:1
11,503 shares0Common Stock, par value $.0001 per shareSEC:0001193125-26-110801:0
11,445 shares0Common Stock, par value $.0001 per shareSEC:0001193125-26-110790:0
21,261 shares0Common Stock, par value $.0001 per shareSEC:0001193125-26-110770:0
85,045 shares0Common Stock, par value $.0001 per shareSEC:0001193125-26-110759:0
22,804 shares@ US$6.8220.5% of flowCommon Stock, par value $.0001 per shareSEC:0001193125-26-027202:1
55,902 shares0Common Stock, par value $.0001 per shareSEC:0001193125-26-027202:0
10,467 shares@ US$6.493.5% of flowCommon Stock, par value $.0001 per shareSEC:0000950170-25-093464:1
12,346 shares@ US$6.497.7% of flowCommon Stock, par value $.0001 per shareSEC:0000950170-25-093472:1
24,193 shares0Common Stock, par value $.0001 per shareSEC:0000950170-25-093472:0
32,258 shares0Common Stock, par value $.0001 per shareSEC:0000950170-25-093464:0
5,725 shares@ US$6.227.7% of flowCommon Stock, par value $.0001 per shareSEC:0000950170-25-084872:1
5,725 shares@ US$6.2217.6% of flowCommon Stock, par value $.0001 per shareSEC:0000950170-25-084874:1
5,725 shares@ US$6.2236.5% of flowCommon Stock, par value $.0001 per shareSEC:0000950170-25-084875:1
5,725 shares@ US$6.2217.6% of flowCommon Stock, par value $.0001 per shareSEC:0000950170-25-084856:1
5,725 shares@ US$6.2217.6% of flowCommon Stock, par value $.0001 per shareSEC:0000950170-25-084873:1
25 of 225 declarations
About Siga Technologies Inc
SIGA Technologies, Inc. is a United States biopharmaceutical company listed on the Nasdaq Global Market, with headquarters in New York. Founded in the 1990s, SIGA has evolved into a highly focused medical-countermeasures and biodefense specialist. Unlike diversified pharmaceutical groups, the company is centered on a narrow portfolio built around its lead asset, TPOXX® (tecovirimat), an antiviral designed for the treatment of human smallpox and, in certain jurisdictions, other orthopoxvirus-related conditions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001010086/000143774925007056/siga20241231_10k.htm?utm_source=openai))
SIGA’s business model is primarily anchored in government procurement and public-health preparedness. The company sells TPOXX largely to the U.S. government and to international government customers or government-affiliated entities. That makes SIGA a niche supplier at the intersection of healthcare, national security, and biodefense readiness. The upside of this model is that it offers a strategic position in a highly specialized category with long-duration institutional relationships; the trade-off is a high degree of concentration around a single commercial platform and a limited number of customers and contract channels. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1010086/000143774926007557/siga20251231_10k.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, SIGA is not trying to compete head-on with broad-based pharmaceutical companies. Its market position is more akin to a strategic biodefense provider with expertise in antiviral countermeasures. Management describes its growth strategy around four priorities: sustaining its partnership with the U.S. Government, advancing regulatory approvals for TPOXX in new indications and formulations, expanding global access through strategic partnerships, and leveraging its capabilities into adjacent therapeutic areas. ([investor.siga.com](https://investor.siga.com/?utm_source=openai))
TPOXX is SIGA’s flagship product and the core of the company’s commercial identity. Recent company disclosures indicate that oral TPOXX is approved in the U.S. and Canada for smallpox, and authorized in Europe, the UK, and Japan for smallpox, mpox (monkeypox), cowpox, and complications following smallpox vaccination. SIGA also continues to work on additional formulations and regulatory pathways, including pediatric development work and potential U.S. label expansion efforts. ([investor.siga.com](https://investor.siga.com/investors/news/news-details/2025/SIGA-Reports-Financial-Results-for-Three-and-Nine-Months-Ended-September-30-2025/default.aspx?utm_source=openai))
Recent milestones reinforce the company’s specialized profile. In May 2026, SIGA reported first-quarter 2026 results and said it remained on track to deliver approximately $13 million of oral TPOXX to an international customer in the second quarter of 2026. The company has also indicated a potential 2026 supplemental NDA submission in the U.S. for a smallpox post-exposure prophylaxis indication, subject to ongoing analysis. For investors, SIGA remains a high-conviction specialty healthcare name whose performance is closely tied to government demand, regulatory developments, and biodefense procurement cycles. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1010086/000114036126019538/ef20072552_ex99-1.htm?utm_source=openai))
